We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
|The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.|
|Release Date:||January 23, 2017|
|Expiration Date:||January 22, 2018|
|Estimated Time to Complete Activity:||30 minutes|
|Fee for Activity:||There is no fee for participating in this activity.|
This breast cancer thought leader discussion, with associated slide deck and eNewsflash, will provide participants with valuable updates and expert perspectives on exciting new data on the treatment of advanced breast cancer released at the 2016 Annual Breast Cancer Meeting in San Antonio, Texas.
|Abstract #P4-22-16:||First-line ribociclib + letrozole in patients with HR+, HER2- advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial|
|Abstract #P4-22-05:||First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial|
|Abstract #P4-22-03:||Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies|
|Abstract #P4-22-06:||Treatment post progression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3|
|Abstract #P6-11-11:||Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1|
|Abstract #P6-11-12:||Subgroup analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2- metastatic breast cancer (MBC) following chemotherapy|
|Abstract #S4-07:||BELLE-3: A Phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment|
|Abstract #S1-02:||PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy|
After successful completion of this educational activity, participants should be able to:
This educational activity is specifically designed for medical oncologists, translational scientists, and other healthcare professionals interested in and/or involved in the treatment of breast cancer.
The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.
This activity is provided by prIME Oncology.
This educational activity is supported by a grant from Novartis Oncology.
Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.
Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.